^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TFEB (Transcription Factor EB 2)

    i
    Other names: TFEB, Transcription Factor EB 2, Class E Basic Helix-Loop-Helix Protein 35, BHLHE35, BHLHe35, TCFEB, T-Cell Transcription Factor EB, ALPHATFEB
    3d
    TFEB confers resistance against the chemotherapeutic agent CX-5461. (PubMed, Autophagy Rep)
    Interfering with TFEB improved the sensitivity of cancer cells to both CX-5461 and gemcitabine. Our findings suggest that TFEB provides broad protection against the stress caused by chemotherapeutic drugs, representing a promising target for intercepting chemoresistance and improving the efficacy of anticancer agents.
    Journal
    |
    TFEB (Transcription Factor EB 2)
    |
    gemcitabine • pidnarulex (CX-5461)
    9d
    Jatropadanes A-Q, lathyrane diterpenoids with lysosomal biogenesis potential from Jatropha podagrica Hook. (PubMed, Phytochemistry)
    Jatropodane A (1) forms a 5/5/10/3 ring system, with a new oxygen bridge between C-14 and C-5. Jatropadane B (2) promoted lysosomal biogenesis through the activation of the transcription factors TFEB/TFE3, whereas its inhibitory effects on the proliferation of HepG2 cells were attenuated by the autophagy inhibitor or the knockdown of TFEB and TFE3, suggesting that lysosomal biogenesis and autophagy induced by jatropadane B (2) are favorable programmed death of tumor cell lines.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • TFEB (Transcription Factor EB 2)
    10d
    Mammalian lipophagy: process and function. (PubMed, Autophagy)
    In contrast, this review focuses specifically on mammalian lipophagy by synthesizing the latest mechanistic insights into receptor-mediated recognition, transcriptional regulation, and signaling integration. We also outline unresolved questions and conceptual gaps - such as how lipophagy is selectively activated, how it coordinates with lipolysis, and whether distinct receptor codes exist in tissue- and disease-specific contexts - that remain unanswered in the current literature.
    Review • Journal
    |
    SQSTM1 (Sequestosome 1) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • TFEB (Transcription Factor EB 2) • PPARA (Peroxisome Proliferator Activated Receptor Alpha) • TP53INP2 (Tumor Protein P53 Inducible Nuclear Protein 2)
    15d
    Central Role of MITF/TFE Family Transcription Factors in Diverse Clear and Granular Cell Tumors. (PubMed, Am J Pathol)
    A principal function of these transcription factors concerns cytoplasmic organellar biogenesis: TFEB is the master regulator of lysosome biogenesis while MITF controls the biogenesis of lysosome-related organelles known as melanosomes which are responsible for melanin pigment production. Here we review the role of MITF/TFE pathway activation in a variety of benign and malignant tumors, with an emphasis on the diverse oncogenic mechanisms that activate this pathway and the resulting altered cell biology that contributes to the distinctive histomorphologic features.
    Review • Journal
    |
    MITF (Melanocyte Inducing Transcription Factor) • TFEB (Transcription Factor EB 2)
    18d
    Clinicopathological and molecular features of acquired cystic disease-associated renal cell carcinoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
    ACD-RCC is a rare renal cell carcinoma that occurs in patients with end-stage renal disease and has unique morphological features. It is often associated with favorable prognosis and alterations in genes related to the MTOR/TSC pathway or chromatin modification.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • KMT2C (Lysine Methyltransferase 2C) • TSC2 (TSC complex subunit 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • TSC1 (TSC complex subunit 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • MME (Membrane Metalloendopeptidase) • KMT2B (Lysine Methyltransferase 2B) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8) • TFEB (Transcription Factor EB 2)
    |
    TP53 mutation
    18d
    Lys-ing the Resistance: Targeting Lysosomes to Overcome Chemoresistance in Ovarian Cancer. (PubMed, Curr Oncol Rep)
    For decades, ovarian cancer (OC) therapy has mainly relied on a regimen of tumor resection followed by treatment with cisplatin and paclitaxel. Finally, lysosomal signaling pathways disrupt various cell death mechanisms such as apoptosis, necroptosis, and ferroptosis, which allow cancer cells to evade death under chemotherapeutic stress. Targeting lysosomal biogenesis, stage-specific autophagy modulation, and lysosome-dependent metabolic vulnerabilities are promising avenues for sensitization of chemoresistant OC cells.
    Review • Journal
    |
    TFEB (Transcription Factor EB 2)
    |
    cisplatin • paclitaxel
    23d
    Toripalimab Combined with Lenvatinib for Postoperative Adjuvant Therapy in Non-Clear Cell Renal Cell Carcinoma with High Recurrence Risk: An Evaluation of Efficacy and Safety (ChiCTR2500113091)
    P=N/A, N=60, Not yet recruiting, The Third Medical Centre, Chinese PLA General Hospital; The Third Medical Centre, Chinese PLA General Hospital
    New trial
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • FH (Fumarate Hydratase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • TFEB (Transcription Factor EB 2)
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)
    1m
    TFE-Altered Renal Cell Carcinoma: A Contemporary Review With Practical Insights and Diagnostic Pearls for Surgical Pathologists. (PubMed, Adv Anat Pathol)
    Given their ability to mimic one another as well as more common RCC subtypes, we present a review here that summarizes relevant morphologic, immunohistochemical, and molecular findings as well as a practical approach to diagnosis. Accurate diagnosis of TFE-altered RCCs is critical to provide patients and treating clinicians with pertinent prognostic information and inform treatment decisions in the event of advanced disease.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • ASPSCR1 (ASPSCR1 Tether For SLC2A4) • TFEB (Transcription Factor EB 2)
    1m
    Low-dose Simvastatin protects pancreatic cancer cells by promoting mitochondrial autophagy through TFEB. (PubMed, Cell Oncol (Dordr))
    These findings may explain one of the reasons for the suboptimal efficacy of simvastatin in the treatment of pancreatic cancer, while also providing new insights for research on the antitumor effects of statins.
    Journal
    |
    SQSTM1 (Sequestosome 1) • TFEB (Transcription Factor EB 2)
    |
    erastin • simvastatin
    1m
    Nrf2 shapes response to lysosomal inhibition of radiation-induced senescent thyroid cancer cells. (PubMed, Endocr Relat Cancer)
    The disruption of the autophagic flux leads to the accumulation of SQSTM1/p62, which in turn activates the Nrf2 pathway. In contrast to cells with functional autophagy, Nrf2-activated cells display a higher tolerance to oxidative stress, making them resistant to the senolytic activity of lysosomal inhibitors.
    Journal
    |
    SQSTM1 (Sequestosome 1) • TFEB (Transcription Factor EB 2)
    1m
    Renal cell carcinoma with biphasic morphology: A cohort showing similar morphology but distinct clinicopathological and molecular features. (PubMed, Pathol Res Pract)
    In TFE3-rearranged RCC, the fusion gene might influence morphology or PD-L1 expression, thereby be likely to affect the efficacy of immunotherapy. Assessment of a combination of histological morphology, immunophenotype, and genetic alterations can facilitate precise pathological diagnosis of RCC, supporting personalized targeted therapy and prognosis assessment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • GPNMB (Glycoprotein Nmb) • CTSK (Cathepsin K) • TFEB (Transcription Factor EB 2)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    PD-L1 IHC 22C3 pharmDx